Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens

Shiyu Jiang, Yan Qin, Peng Liu, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Changgong Zhang, Liqiang Zhou, Yan Sun, Yuankai ShiJournal of Cancer 2020 · DOI

Introduction

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. While standard R-CHOP therapy (rituximab plus chemotherapy) cures approximately 60% of patients, the remaining 30–40% develop relapsed or refractory (r/r) disease. For these patients, the prognosis is often poor, and traditional tools like the International Prognostic Index (IPI) are less effective in the modern post-rituximab era. This study aimed to identify key predictors and construct a prognostic nomogram for risk stratification in r/r DLBCL patients who failed initial R-CHOP treatment.

Methods

The researchers conducted a retrospective study of 296 r/r DLBCL patients treated at the Cancer Hospital, Chinese Academy of Medical Sciences, between 2006 and 2017. A total of 231 eligible patients were randomly assigned to a primary cohort (n=161) for model construction and a validation cohort (n=70) for testing. Multivariate Cox proportional hazards regression was used to identify independent prognostic factors for Overall Survival (OS). Additionally, ordinal regression analysis was employed to identify factors predicting the efficacy of second-line therapy.

Key Results and Nomogram Development

The final prognostic model integrated four independent clinical variables:

  1. Rituximab in second-line treatment: Surprisingly, including rituximab in salvage therapy remained beneficial even after initial R-CHOP failure.
  2. Initial ECOG Performance Status (PS): Baseline physical status was a significant predictor of long-term outcomes.
  3. Response to front-line treatment: Patients who achieved Complete or Partial Remission (CR/PR) initially had significantly better survival than primary refractory patients (SD/PD).
  4. Invasion pattern on recurrence: Patients with cancer appearing in entirely new sites fared better than those with recurrence in original sites or both.
The prognostic nomogram integrates four clinical factors to predict 3-year and 5-year overall survival probabilities.

The resulting nomogram demonstrated solid predictive accuracy, achieving a C-index of 0.70 and AUC values of 0.73 and 0.71 in the primary and validation cohorts, respectively.

Risk Stratification and Survival Outcomes

Using the nomogram scores, patients were stratified into three distinct risk groups with significantly different survival profiles:

  • Low Risk: Median Overall Survival (OS) of 38.0 months.
  • Intermediate Risk: Median OS of 25.0 months.
  • High Risk: Median OS of only 7.0 months.
Kaplan-Meier survival curves demonstrate significant differences in overall survival across the low, intermediate, and high-risk groups (p < 0.0001).

Furthermore, the study identified that a prior positive response to front-line treatment and the absence of bulky disease at diagnosis were the two strongest independent predictors of second-line treatment success.

Discussion and Limitations

While the nomogram provides a valuable tool for risk stratification, the study has limitations. As a retrospective, single-center study, the findings may be influenced by selection bias. Additionally, the rate of Autologous Stem Cell Transplant (ASCT) was lower than in many Western cohorts, which may affect generalizability. Future research should focus on validating these findings in larger, multi-center trials and incorporating molecular biomarkers to further refine the model's accuracy.

Conclusion

This novel nomogram offers a practical roadmap for personalized treatment in the post-rituximab era, helping clinicians identify high-risk patients who may require more aggressive or experimental therapeutic interventions.

Summary updated

Abstract

<b>Background</b>: The clinical course of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) is variable, with limited efficacy data of second-line treatment in a post-rituximab real-world context. Hence, we explored the predictors and constructed a nomogram for risk stratification in this population. <b>Patients and methods</b>: Among 296 r/r DLBCL patients pretreated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) at the Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College between 2006 and 2017, 231 were included for nomogram construction. After randomization, we constructed the prognostic nomogram in the primary cohort (n=161) based on a multivariate analysis and confirmed it in the validation cohort (n=70). Additionally, we explored predictive factors for second-line therapy using a ordinal regression analysis. <b>Results</b>: Four independent prognostic factors including rituximab in the second-line setting, initial Eastern Cooperative Oncology Group (ECOG) performance status (PS), response to front-line treatment, and invasion on progression/recurrence were used to construct the nomogram. The nomogram had a C index of 0.70 with AUC values of 0.73 and 0.71 for the primary and validation cohorts, respectively. Subsequently, three risk groups (low, intermediate, and high) were determined with median overall survival (OS) of 38.0, 25.0, and 7.0 months, respectively. Additionally, we conducted a multivariate ordinal regression analysis and identified prior response to front-line treatment (odds ratio=4.50, 95% CI: 1.84-11.27, p=0.001) and bulky disease at diagnosis (odds ratio=0.36, 95% CI: 0.182-0.702, p=0.003) were two independent factors for second-line treatment efficacy. <b>Conclusions</b>: The established predictors for treatment efficacy and the novel nomogram for survival in r/r DLBCL patients could potentially be applied for risk stratification and treatment guidance in the post-rituximab era.
BibTeX
@article{jiang2020prognostic,
  author = {Shiyu Jiang and Yan Qin and Peng Liu and Jianliang Yang and Sheng Yang and Xiaohui He and Shengyu Zhou and Lin Gui and Changgong Zhang and Liqiang Zhou and Yan Sun and Yuankai Shi},
  title = {{Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens}},
  journal = {Journal of Cancer},
  year = {2020},
  doi = {10.7150/jca.36997},
}
Figure